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Review Article
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Abstract: As numerous new therapies against non-Hodgkin lymphoma (NHL) are under investigation, 
there is an increasing interest in surrogate endpoints (SEPs) that can reduce the costs and duration of 
clinical trials and thereby accelerate delivery of new treatments to patients with unmet medical needs. The 
time to normalization of overall survival (OS) is an endpoint that is increasingly explored for this purpose. 
The patient survival is considered normalized when it matches the corresponding survival of a matched 
background population. The time point where this occurs is also useful for patient counselling and for 
developing rationale clinical follow-up programs. Survival normalization has been investigated in both 
aggressive and indolent NHLs with some results indicating survival normalization after 24 months of event-
free survival (EFS24) in diffuse large B-cell lymphoma (DLBCL) patients and for patients with follicular 
lymphoma (FL) with complete response after 30 months (CR30). Here, we review the concept of survival 
normalization endpoints and their potential as SEPs in future NHL trials. As intervention effects on SEPs 
should adequately predict effects on conventional endpoints, validation generally requires extensive analysis 
of data from multiple trials, and thus only few validation studies exist within cancer. The validity of EFS24 
and CR30 as surrogates for OS and progression-free survival (PFS), respectively, was investigated in a series 
of trials from the Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) and Surrogate Endpoints 
for Aggressive Lymphoma (SEAL) consortiums. The results suggested a strong correlation between 
CR30 and PFS results in FL, whereas the correlation between intervention effects on the EFS24 endpoint 
and OS in DLBCL did not met prespecified thresholds despite clear correlation. In conclusion, survival 
normalization is a clinically important concept, but more research is needed before the EFS24 endpoint can 
be applied in future DLBCL trials. On the other hand, results suggest that CR30 may be a suitable SEP for 
PFS in future FL trials.
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Background
Overall survival (OS) is considered the gold standard 
and the most definitive endpoint for measuring cancer 
outcomes, with non-Hodgkin lymphomas (NHLs) being 
no exception to this dogma. OS is unaffected by different 
follow-up routines and clinical investigations for disease 
progression as well as subjective interpretation of disease 
status based on these investigations—typical biases 
inherent to endpoints like progression-free survival (PFS). 
However, OS is not perfect as it also measures the efficacy 
of interventions and treatment decisions subsequent 
to progression, which can lead to systematic bias if the 
intervention of interest influences these later decisions. In 
contrast to the majority of solid cancers, NHLs, such as 
follicular lymphoma (FL) and diffuse large B-cell lymphoma 
(DLBCL), are typically very chemosensitive diseases and 
long-term survival is achieved in a substantial fraction of 
the patients. In DLBCL, 60–70% of the patients achieve 
durable remissions after first-line therapy with R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone), and will be without need of further lymphoma 
therapy during the rest of their lifetime (1). The remaining 
30–40% are either refractory to first-line treatment, relapse 
after initial response, or fail to complete first-line therapy 
due to toxicity leading to dismal outcomes (2,3). Non-
localized indolent NHLs such as FL or Waldenström’s 
macroglobulinemia (WM) are incurable with conventional 
therapies, but long remissions between treatments are 
common and approximately 80% of immunochemotherapy-
treated FL patients are projected to be alive 10 years after 
diagnosis (4-6). Thus, indolent NHLs are often chronic 
diseases with long disease-free periods between treatments, 
although remissions tend to become shorter with each 
new therapeutic intervention (7,8). The differences in 
the natural history of aggressive and indolent NHLs have 
implications for selection of endpoints in clinical trials, 
which should reflect the balance between expediting clinical 
trials benefitting patients with unmet medical needs and 
protecting patient safety, while ensuring that the measured 
benefit of new therapies translates into relevant outcome 
improvements for patients. Surrogate endpoints (SEPs) 
that allow faster readout of study results are of increasing 
interest in cancer research and time points from which the 
patient survival becomes identical to that of a background 
population are among the potential SEPs in NHL trials. 
Furthermore, such time points are valuable for patient 
counselling and designing rational survivorship care. In 
this narrative review, the concept of deriving landmark 
time points from which no excess mortality exists for 
NHL patients is reviewed from a statistical and clinical 
perspective. We present the following article in accordance 
with the Narrative Review reporting checklist (available at 
http://dx.doi.org/10.21037/aol-20-4).
Normalization of survival
True cure in the sense of never experiencing relapse 
throughout the remaining lifetime of a patient can only be 
concluded after lifelong follow-up, and this individual-level 
definition of cure is therefore not relevant for SEP purposes. 
Instead, the definition of cure can be based on a quantification 
of the residual life expectancy of the patients (9). 
At diagnosis, the mortality of NHL patients is typically 
higher than for a matched background population due to 
the risk of dying from treatment refractory disease, relapse, 
or treatment complications. However, as time elapses, the 
patient survival may gradually approach that of similarly 
aged individuals in the background population as the risk 
of the aforementioned events decrease. Patients could be 
considered cured if they reach the time point where the 
mortality risk for the patient population becomes identical 
to that of a matched background population. As this 
population-level definition of cure only applies on a grouped 
patient level, and therefore does not guarantee freedom of 
later disease relapses on the individual-level, it has often 
been called “statistical cure” (10). For the remainder of 
this review we will use the term “survival normalization”. 
Two main indicators are commonly considered for survival 
normalization: (I) the time to survival normalization 
(TTSN), defined as the time point from which the residual 
life expectancy among the patients becomes similar to 
that of the matched background population, and (II) the 
proportion of the patients who are still alive when survival 
normalization is reached, termed “the cure fraction” (9). 
The TTSN is the time point from which patients, in this 
case NHL patients, face similar risk of death as individuals 
without NHL. A statistical quantification of the difference 
between the patient and background population mortality 
is required to determine the TTSN. Standardized mortality 
ratios (SMRs), i.e., the fraction of observed number of 
deaths to the expected number of deaths (in the matched 
background population) and the loss of expected lifetime 
(LEL) are frequently used for this purpose (11,12). The 
cure fraction and 5-year relative survival have also been 
applied (9,13-15). The advantages and disadvantages 
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of different measures are discussed in detail in a recent 
overview of methods for estimating the TTSN (16).
As the concept of survival normalization has provided 
valuable insights into the prognosis of various NHLs in 
several recent studies, it is worth taking a deeper look into 
some of the potential limitations of the applied methods. 
From a statistical perspective, determining TTSN is 
complex as the number of patients at risk in a study becomes 
smaller with increasing follow-up and thereby weakening 
the power of statistical tests to detect a true difference 
between the patient and background population. Therefore, 
TTSN findings could be a result of underpowered statistical 
tests and researchers could falsely conclude survival 
normalization too early (Figure 1) (17). Instead of relying on 
statistical tests for detection of the TTSN, the LEL may be 
used to quantify the expected number of years lost due to 
a specific disease. This is computed by calculating the area 
between the patient and background population survival 
curves until a given time point, e.g., 5 or 10 years (Figure 2). 
This is often referred to as the restricted LEL, as it only 
provides the number of life years lost within a specific time 
window. Since the restricted LEL does not capture the 
impact of the disease on survival over a longer period, for 
example the full lifetime of an individual, this has prompted 
extrapolations of both the patient and background 
population survival curves beyond the observed follow-
up to quantify the LEL over the full lifetime of patients 
(18,19). However, extrapolations are by nature prone to 
uncertainty as they rely on survival assumptions beyond 
the available data points and without possibility to confirm 
the accuracy of the applied assumptions. Extrapolation to 
estimate the total LEL has been tested within colon cancer, 
breast cancer, malignant melanoma, and bladder cancer 
with varying accuracy (18,20). Improved extrapolations may 
be obtained by using approaches that utilize data with long 
follow-up, such as population-based registers or background 
population mortality rate tables (21). Assumptions can then 
be based on the expected survival difference between the 
patients and the background population without need for 
assumptions directly on the patient survival. Nonetheless, 
the validity of the extrapolations remain untestable 
and there is no guarantee against biased extrapolations 
affecting the total LEL (18). Even if a model fits the data 
well within the observed follow-up, extrapolations based 
on the same model may perform poorly. Finally, the 
likelihood of large extrapolation biases increases if the 
expected residual lifetime of the patients is long, as seen in 
Hodgkin lymphoma patients (22,23), because extrapolation 
over a longer time period is required. Sudden changes in 
outcomes, for example due to a rise in the incidence of fatal 
late complications such as secondary cancers, may also lead 
to poor extrapolations.
Another potential bias when comparing NHL patient 
survival to the survival of the background population is 
systematic selection of fit patients for treatment. This is 
particularly relevant when assessing elderly patients, as an 
Figure 1 Overall survival (A) from diagnosis, (B) from the two-year event-free survival landmark, and (C) from the five-year event-free 
survival landmark of a hypothetical NHL patient group and the background population matched on age, sex, and calendar year. For patients 
event-free after five years, the survival seems slightly lower than the background survival, but the SMR is no longer significantly different 
from one, suggesting survival normalization, which may be a result of few patients remaining at risk after five years. SMR, standardized 
mortality ratio.
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elevated mortality beyond the identified TTSC may still 
exist if the NHL patient population is not matched to an 
identically fit background population, i.e., the differences 
between the patients and the background population is not 
limited to the presence of NHL. Additionally, frail NHL 
patients will be at increased risk of dying early during 
therapy due to complications or suboptimal treatment 
leading to poor disease control. Therefore, the patient 
population could be gradually enriched for a fitter patient 
segment over time which may lead to biased comparisons 
to a background population that has not been exposed to a 
similar selection process (24).
Survival normalization models for use in clinical 
practice
After the diagnosis of NHL, most patients engage 
actively in discussions with health care professionals about 
treatment options, possible treatment outcomes, and 
treatment toxicities. Many patients express a wish to know 
their prognosis which is typically assessed by using clinical 
prognostic scores such as the International Prognostic 
Index (IPI) and the FL International Prognostic Index 
(FLIPI) (25,26). The prognostic scores group the patients in 
3–4 groups based on the number of risk factors present. The 
survival outcomes within each of the prognostic subgroups 
are then typically reported as 5-year OS estimates which in 
DLBCL ranges between >80% for low risk disease (IPI =0) 
and <40% for high risk disease (IPI >2) (27). While these 
measures are relevant for summarizing disease burden for 
groups of patients and facilitate comparisons of outcomes 
across institutions and clinical trials, they are not optimal for 
patient counselling. For example, a four-year OS estimate of 
59% is detrimental information for a 20-year-old DLBCL 
patient with high-risk disease (IPI 4–5) due to poor Eastern 
Cooperative Oncology Group (ECOG) performance 
score caused by massive mediastinal bulk disease, extensive 
extranodal involvement, and elevated LDH. On the contrary, 
an 80-year-old with advanced stage disease, elevated lactate 
dehydrogenase and poor performance due to age-related 
comorbidities with similar IPI-predicted 4-year survival 
of 59% may find great comfort in this information. The 
same prognostic information can be perceived so differently 
because crude 5-year OS estimates do not account for the 
differences in expected residual lifetime between a 20-year-
old and an 80-year-old patient. Another caveat of using 
Figure 2 The survival curve for ten hypothetical patients and the background population matched on age, sex, and calendar year. The 
observed number of deaths among the patients within the follow-up is 8 and the expected number of deaths in the background population 
is 3.1, leading to an SMR of 2.6 (95% CI, 1.1–5.0). Testing whether the SMR is significantly different form 1 yields a P value of 0.03. The 
blue area indicates the difference in 5-year restricted mean survival time between the patients (2.25 years; 95% CI, 1.08–3.41) and the 
background population (5.17), i.e., the 5-year restricted loss in expectation of life (2.93 years; 95% CI, 1.76–4.09). The total LEL is obtained 
by computing the area between the curves until both curves have reached zero, i.e., the sum of the blue and green area. SMR, standardized 
mortality ratio; LEL, loss of expected lifetime.
0 2 4 6 8 10 12
Years since diagnosis
O
ve
ra
ll 
su
rv
iv
al
 (%
)
100
80
60
40
20
0
Unobserved periodFollow−up period
Annals of Lymphoma, 2020 Page 5 of 11
© Annals of Lymphoma. All rights reserved.   Ann Lymphoma 2020;4:5 | http://dx.doi.org/10.21037/aol-20-4
5-year OS for patient counselling is that 5-year OS estimates 
of less than 100% can be received with disappointment by 
patients for whom 100% OS may be synonymous with cure. 
Missing the opportunity to integrate normal life expectancy 
in the prognostic assessments can thus cause confusion. 
Finally, the use of prognostic scores calculated at diagnosis 
does not reflect the significant changes in prognosis as the 
patient reaches different milestones during treatment and 
follow-up.
Landmark analyses in DLBCL
The first study to analyze TTSN in DLBCL was an 
American-French study including 767 patients from the 
University of Iowa/Mayo Clinic Specialized Program of 
Research Excellence Molecular Epidemiology Resource 
(MER) and the North Central Cancer Treatment Group 
(NCCTG-N0489), all treated with immunochemotherapy 
and followed for a median of 5 years. The patient survival 
was compared to the survival of a matched background 
population and SMRs of observed to expected number of 
deaths were calculated at diagnosis for all patients and for 
patients reaching 12 and 24 months of event-free survival 
(EFS) (11). EFS was defined as the time from diagnosis 
until progression/relapse, unplanned NHL treatment, or 
death from any cause. At diagnosis, DLBCL patients had 
significantly increased risk of death as compared to the 
matched background population, which was reflected by an 
SMR of 2.88 (95% CI, 2.51 to 3.31). The SMR dropped 
to 1.40 (95% CI, 1.10 to 1.76) for patients reaching the 
EFS12 milestone, while the SMR was not significantly 
different from 1 (1.18, 95% CI, 0.57 to 1.57) for patients 
reaching the EFS24 milestone, suggesting normalized 
survival (11). The results were validated in a French cohort 
of 820 newly diagnosed DLBCL patients with a median 
follow-up of 42 months. Despite normalized survival at the 
EFS24 milestone, the DLBCL patients remained at risk of 
relapse with 8% of patients achieving EFS24 relapsing in 
the following 5 years. Thus, the TTSN does not imply true 
cure from NHL (11). The fact that relapses were not rare 
after EFS24, yet did not prevent survival normalization, 
supports that time from diagnosis to relapse is an important 
predictor of survival and that late relapses are generally 
more responsive to salvage therapies (28,29). Importantly, 
the IPI risk factors lost their prognostic value over time 
and was no longer predictive of outcome in patients 
reaching the EFS24 milestone. The results of this study 
were immediately applicable for patient counselling and 
spurred a widespread interest in TTSN milestones (12,22). 
After establishing EFS24 as an important milestone for 
DLBCL patients, the development of tools that predict the 
likelihood of achieving EFS24 was a natural next step to 
provide personalized prognostic information to DLBCL 
patients. Based on eight routinely collected clinical factors, 
a prediction model was developed in 1,348 patients treated 
with immunochemotherapy and successfully validated in 
an independent cohort of 1,177 patients (30). The model 
provides a personalized probability between 0% and 
100% of reaching the EFS24 milestone and has improved 
discriminatory ability (C-statistic =0.671) over both IPI 
(C-statistic =0.649) and the National Comprehensive 
Cancer Network IPI (C-statistic =0.657).
The importance of reaching specific time points without 
events was later confirmed in nationwide population-based 
studies. A Danish Lymphoma Registry study investigated 
the TTSN in a cohort of DLBCL patients in complete 
remission (CR)/unconfirmed (CRu) after first-line 
R-CHOP-like treatment (12). Similarly to the American-
French study, this study showed increased mortality after 
completion of first-line immunochemotherapy, despite all 
analyzed patients being in CR/CRu (SMR, 1.75, P<0.001). 
A small but significant excess mortality (SMR, 1.27, 
P<0.001) remained for patients in remission for 24 months 
and persisted even for patients in remission 48 months after 
therapy. However, the restricted LEL was substantially 
reduced after two years in remission. The small divergence 
between the US and Danish data may be explained by the 
nationwide scale of the Danish Lymphoma Registry, thereby 
reducing potential selection bias when comparing patient 
survival to that of the Danish background population. 
Notably, for patients <50 years of age, survival normalization 
was observed after 2 years possibly because the few late 
relapses in young DLBCL patients are likely to be cured 
with intensive salvage therapies and autologous stem cell 
transplantation. Consistent with the American-French 
results, IPI was no longer prognostic after 24 months. 
Both the French-American and Danish studies are limited 
by a relatively short follow-up, making extrapolation and 
full evaluation of LEL uncertain.
A more recent population-based study of LEL in DLBCL 
was based on the Swedish Lymphoma Registry (19). Unlike 
the two previous studies, this study examined trends over 
time in LEL and was not restricted to patients treated with 
R-CHOP(-like) therapies. Furthermore, OS time points 
after diagnosis, and not EFS or PFS time points like the two 
previous studies, were used to estimate potential survival 
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normalization of DLBCL as data on DLBCL relapse were 
not available in the registry throughout the surveyed time 
period [2000–2013]. Rather than reporting SMRs, the 
Swedish study modelled LEL using flexible parametric 
survival models for all patients and for patients reaching the 
2-year OS landmark. Extrapolations were used to compute 
the total LEL. Compared to the median age of 63 years in 
the MER cohort and 65 years in the Danish Lymphoma 
Registry study, the median age in the Swedish population-
based study was 70 years, likely a result of not applying 
any restrictions on first-line chemotherapy. The study 
documented a decrease in LEL when comparing patients 
treated before and after the introduction of rituximab as 
standard therapy for DLBCL; LEL decreased from 8.0 
to 4.6 years over the study period. The reduction in LEL 
was most pronounced for younger patients between 50 and 
60 years and with age-adjusted IPI (aaIPI) ≥2 showing a 
decrease in LEL from 17.5 to 8.6 years for 50-year-old male 
patients from 2000 to 2013 and 18.4 to 9.1 years for female 
patients (19). For 50-year-old male patients with high 
risk disease reaching the two-year OS landmark in 2012, 
the LEL was no longer significantly increased (1.1 years, 
95% CI, −2.3 to 4.5 years). For patients with aaIPI ≤2 and 
>2, LELs were reduced substantially from 3.8 and 6.1 years, 
respectively, at diagnosis to around 1 year for both groups 
after the two-year OS landmark. This study showed that 
the improvement in DLBCL outcomes over the surveyed 
time period was substantially stronger than the general 
increase in the life expectancy of the Swedish background 
population observed in the same era. OS landmarks are not 
directly comparable to PFS and EFS landmarks as patients 
who relapse before the 24 month landmark may reach the 
2-year OS, but have a substantially increased risk of death 
compared to patients free of adverse events until the two-
year landmark (11,12,19). Thus, for patient counselling 
and planning rational survivorship care, the PFS and EFS 
landmarks are more informative and provides a basis for 
more individualized risk assessment.
Landmark analyses in FL and marginal zone lymphoma 
(MZL)
Investigations of TTSN have also been performed in 
indolent NHLs. Casulo et al. evaluated the impact of 
progression of FL within two years of diagnosis in patients 
treated with first-line R-CHOP. The study demonstrated 
significantly reduced 5-year OS among patients with 
early progression (50%) compared to patients without 
events in the first two years (90%). In that study, survival 
was measured from the time of progression or from the 
two-year landmark in patients without progression (31). 
Normalization of OS in FL patients has previously been 
investigated using data from the American MER on 920 
newly diagnosed FL patients and 412 FL patients from 
two French registries (32). The study revealed poor OS for 
patients with events within 12 months of diagnosis, whereas 
patients who remained event-free for 12 months did not 
have higher mortality rate than the background population 
(SMR, 0.73, 95% CI, 0.56–0.94). Among patients who 
initiated immunochemotherapy and remained event-free 
in the subsequent 24 months, the mortality was no longer 
elevated as compared to the background population (SMR, 
0.37, 95% CI, 0.18–0.78). 
An analysis of 263 Spanish FL patients undergoing 
rituximab containing treatment (median follow-up, 7 years) 
with validation in 693 patients from the GELTAMO group 
database (median follow-up, 6.7 years) explored similar 
research questions (33). This study investigated the clinical 
impact of being in complete response for 30 months after 
start of therapy (CR30), which corresponds to the time 
point for completion of induction therapy and 24 months of 
maintenance therapy. Among patients reaching the CR30 
endpoint (71%), the 10-year relative survival (relative to the 
Spanish background population) was 100%, which was also 
seen in the GELTAMO validation cohort (62% reaching 
CR30), confirming normalization of OS in this subset of FL 
patients. Thus, CR30 appear to be a critical landmark in FL.
In other indolent lymphomas, such as extranodal 
MZL, unclassifiable low-grade B-cell lymphoma, and 
lymphoplasmacytic lymphoma, a recent American study 
by Tracy et al. compared the patient mortality with that 
of the US background population (34). Patients who were 
free of events (death, disease progression, and retreatment) 
12 months after diagnosis experienced mortality rates 
similar to the background population (SMR 1.19, 95% CI, 
0.95–1.46). On the contrary, patients with events within 
12 months after diagnosis had significantly worse survival 
(SMR 3.13, 95% CI, 2.05–4.59) (34). A subsequent study 
exclusively evaluating the prognosis of MZL patients 
with planned immediate treatment after the diagnosis 
highlighted the excellent outcomes of MZL patients 
without adverse events within the first two years following 
diagnosis (35). For patients with disease progression 
within 24 months of diagnosis, the 3-year OS was 53%, 
whereas the survival of patients without progression within 
24 months was 95%. However, because the treatment is 
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generally not considered curable, the very positive outlooks 
for patients free of disease 24 months after diagnosis does 
not guarantee against future detrimental effects on survival 
due to multiple relapses over time.
Early time points for normalization of survival—
ready for clinical trials?
While the majority of patients with DLBCL or FL respond 
to contemporary first-line immunochemotherapy, unmet 
medical needs exist for patients that are refractory or 
experience early relapse. For example, FL patients who 
relapse within the first 24 months after commencing first-
line immunochemotherapy treatment have significantly 
worse OS than patients who achieve more durable 
remissions (5-year OS, 50% vs. 90%) (31,32). For DLBCL, 
first-line treatment has not improved since the addition 
of rituximab to CHOP in the early 2000s (36-38). Several 
attempts to improve the outcomes of DLBCL patients 
have failed, including the use of next generation CD20 
antibodies, chemotherapy intensification with dose adjusted-
EPOCH, and addition of small molecules that target active 
cellular pathways in the activated B-cell phenotype of 
DLBCL (39-43). However, a number of novel therapies 
are currently under evaluation in NHL such as bispecific 
antibodies directing T-cells towards CD20 positive cells 
(NCT03075696), genetically engineered T-cell therapies 
[chimeric antigen-receptor T-cell therapies (CART), 
ZUMA-7: NCT03391466], toxin conjugated antibodies 
(NCT03274492, NCT04150328), and macrophage 
activating anti-CD47 antibodies. These therapies are 
fundamentally different from the typical chemotherapy 
approach for relapsed/refractory NHL and while some are 
only tested in the relapsed/refractory setting, it is likely 
that they are relevant for high-risk DLBCL in the upfront 
setting as well. With the high number of drugs being 
screened for efficacy, it is critical to have reliable endpoints 
that accurately identifies drug candidates with a true benefit 
for the NHL patients. 
SEPs are needed to bring new medicine faster to 
patients and to reduce the costs of clinical trials. In many 
cancer trials PFS and disease-free survival are used as 
preferred SEPs for OS due to their association with OS 
in combination with more events at earlier time points 
enabling faster readout. SEPs are not required to be as 
clinically meaningful as conventional endpoints, but changes 
in the SEPs should reflect changes in the conventional 
endpoint, i.e., the intervention effect based on the SEP 
accurately predicts the effect on the conventional endpoint 
(44,45). Correlation between the conventional endpoint 
and a new SEP is often intuitive or well documented, but 
despite a correlation, the effect of the clinical intervention 
measured with the SEP may be different from the effect 
on the conventional endpoint (44,46). Validating that the 
intervention effect based on the SEP predicts the effect 
on the conventional endpoint can be done by comparing 
the effect obtained on the two endpoints in a series of 
clinical trial data (47). For example, the hazard ratio (HR) is 
commonly used for measuring efficacy in cancer trials, and 
so the correlation between the HRs obtained by using OS 
and PFS as endpoints determines the validity of PFS as a 
SEP for OS. Validating the EFS24 milestone as SEP for OS 
would require a quantification of the correlation between 
the odds ratio (OR), or similar effect measures, for EFS24 
and the HR for OS. As the concordance between the SEP 
and the conventional endpoint effects may be dependent 
on the therapeutic intervention under investigation, data 
from a large number of trials are needed to compute this 
correlation with a high confidence, which often precludes 
the needed rigorous validation of SEPs. Using validated 
SEPs in clinical trials is reasonable when correlation is 
strong. However, there is no consensus on the amount of 
correlation required to define SEPs as valid (46). Various 
methods for quantifying the correlation between the 
SEP and the conventional endpoint have been proposed, 
including simple correlation coefficients, coefficients of 
determination and variations hereof, and proportions of 
agreement (47). Recent lymphoma studies have mainly been 
focusing on the coefficients of determination (48,49). 
While the TTSN may be used as SEP in future trials, 
it comes with a number of caveats. The use of, e.g., EFS24 
as SEP would be based on the assumption that novel 
therapies for DLBCL do not alter the typical course of 
DLBCL and are not associated with severe late toxicities 
that substantially reduces life expectancy beyond the EFS24 
endpoint. A therapeutic intervention could effectively 
achieve short remissions but be associated with serious 
and fatal late toxicities or change relapse kinetics, which 
could lead to erroneous conclusions when EFS24 is used 
as endpoint. Additionally, if the incremental efficacy of an 
intervention on EFS persists beyond the EFS24 milestone, 
using conventional EFS will be statistically more powerful 
than using the EFS24 endpoint. That is, the probability 
of detecting a true effect of the intervention is larger with 
EFS compared to EFS24 (11). On the other hand, if the full 
effect of an intervention occurs within the first 12 months, 
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EFS24 is more powerful than the continuous EFS. Applying 
the EFS24 milestone as a SEP for OS in DLBCL trials 
requires only two years of follow-up for each patient in the 
trial. In comparison, some of the recent DLBCL trials have 
a median follow-up of 31.5–60 months (39,41,42). Besides 
accelerating trial readout, the EFS24 milestone also changes 
the analytical approach from a time-to-event outcome to 
a dichotomous endpoint, which avoids censoring issues, 
although loss to follow-up may still occur. 
The appropriateness of using a PFS24 milestone as SEP 
for OS was recently investigated by correlating the OR 
using the PFS24 endpoint with the HR obtained by using 
the OS endpoint in a series of 13 clinical trials from the 
Surrogate Endpoints for Aggressive Lymphoma (SEAL) 
database conducted in the period 1998–2015 (49). The 
comparison led to a high correlation (R2≥0.75), but the 
correlation did not exceed the pre-defined correlation 
threshold of 0.8 (49). The lack of sufficient correlation 
between the PFS24 OR and the OS HR may be a result of 
the single time point focus of PFS24, whereas the OS HR is 
based on the entire follow-up. Neither changes in prognosis 
beyond PFS24 nor the timing of events before PFS24 are 
taken into account when PFS24 is the primary endpoint, 
and this may cause some discrepancy between trial results 
with PFS24 and OS as endpoint. Thus, correlation between 
PFS24 and OS results is still not sufficiently documented 
and the PFS24 milestone is not suitable for randomized 
trials in DLBCL at this time. 
A similar analysis investigated if the CR30 endpoint 
could be used as SEP for PFS among previously untreated 
FL patients (48). The Follicular Lymphoma Analysis of 
Surrogate Hypothesis (FLASH) group analyzed patient-
level data from 13 trials published after 1990 investigating 
either induction or maintenance therapy. The study 
revealed a high correlation between results using CR30 
and PFS as endpoints, exceeding predefined correlation 
thresholds. It was concluded that the CR30 endpoint is an 
appropriate SEP for PFS in future trials of first-line FL 
therapy. As treatment for FL is typically not considered 
curative and new frontline treatment approaches may 
not necessarily increase OS due to availability of effective 
therapies after progression, improving CR30 is of important 
value for patients as long as it occurs in the absence of 
undue toxicities (50-52). 
Conclusions
Understanding prognosis of NHL relative to the expected 
survival in an age and sex-matched background population 
is valuable for patients, health care planners, and potentially 
also for designing future clinical trials. Prognostic 
information delivered in an understandable language using 
measures that patients can directly relate to is important for 
active and informed engagement of patients and relatives in 
critical treatment decisions. The normalization of survival 
may also have a role as a SEP in future clinical trials to 
provide more rapid readout of study results compared to 
conventional endpoints such OS and PFS. However, from 
a statistical perspective, caution should be given when 
deriving new endpoints based on survival normalization 
because an excess mortality may persist beyond the point of 
survival normalization, especially if the number of patients 
with long follow-up is limited.
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